Regulators crack down on rogue GLP‑1 supply

A fast lane for cheap online weight-loss shots is starting to close. On February 6, 2026, the Food and Drug Administration said companies selling unapproved compounded glucagon-like peptide 1 drugs could face seizure or injunction without further notice. (fda.gov) Those drugs mimic the hormone glucagon-like peptide 1, which helps control appetite and blood sugar. Brand names like Wegovy and Ozempic use semaglutide, and demand got so high in 2022 that shortages opened the door for many compounders to step in. (fda.gov) Compounding is the pharmacy version of custom tailoring. A pharmacy can mix a drug for one named patient, but it generally cannot mass-produce a near-copy of a commercially available medicine just because people want a cheaper version. (fda.gov) That distinction mattered less during the shortage. On February 21, 2025, the Food and Drug Administration formally said the semaglutide injection shortage was resolved after reviewing Novo Nordisk supply and inventory data. (fda.gov) The agency made a similar move on tirzepatide, the Eli Lilly drug sold as Zepbound and Mounjaro. In its April 1, 2026 policy reminder, the Food and Drug Administration said tirzepatide injection shortage conditions had been resolved and re-emphasized that compounders still have to meet the usual legal limits. (fda.gov) The new fight is not only about what is in the vial. It is also about how telehealth companies advertise these products, because the Food and Drug Administration issued more than 55 warning letters on September 16, 2025 over misleading marketing of compounded semaglutide and tirzepatide online. (pharmacytimes.com) The Food and Drug Administration got more specific on April 1, 2026. It said even a semaglutide injection mixed with vitamin B12 can still count as an “essentially a copy” of a commercial drug if the strength and route are close enough. (fda.gov) Novo Nordisk pushed from the private side at the same time. On February 9, 2026, it sued Hims & Hers, saying the telehealth company’s compounded semaglutide products infringed U.S. Patent No. 8,129,343 and used inauthentic active ingredient. (reuters.com) That clash changed fast. On March 9, 2026, Hims & Hers said it would shift its United States weight-loss business toward Food and Drug Administration-approved glucagon-like peptide 1 drugs through a collaboration with Novo Nordisk, while keeping compounded semaglutide only on a limited scale. (investors.hims.com) For patients, the practical difference is simple. The gray-market version that looked like a shortcut was often built on shortage-era rules, and regulators are now treating many of those workarounds like illegal copies rather than emergency substitutes. (fda.gov) The safety angle is not abstract. The Food and Drug Administration says compounded glucagon-like peptide 1 drugs are not reviewed by the agency before sale, and it has warned about dosing mistakes, counterfeit-looking labels, and shipping problems for refrigerated injectables. (fda.gov) So the market is being split in two. Brand-name manufacturers are cutting prices and signing telehealth deals for approved semaglutide, while the Food and Drug Administration is raising the legal risk for sellers that still market copycat versions at scale. (novonordisk-us.com)